Wednesday, October 14, 2026

Alphabet lifts 2026 capex guidance as four hyperscalers commit $650B combined

Alphabet raised its 2026 capital expenditure outlook, adding to a combined $650 billion spending plan among four AI hyperscalers for the year. Vertiv and Nvidia partnered on 800-volt DC power platforms for AI data centers, signaling infrastructure vendors are locking into multi-year buildout commitments.

LM Salvado
LM Salvado

July 30, 2026

Alphabet lifts 2026 capex guidance as four hyperscalers commit $650B combined
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Alphabet raised its 2026 capital expenditure outlook this week, joining three other hyperscalers in a combined spending plan of roughly billions for the year.1 The increase comes despite elevated interest rates that typically discourage large capital outlays.1

The guidance revision is not isolated. Four AI hyperscalers now project combined 2026 capex near billions, indicating the sector's infrastructure buildout is accelerating rather than plateauing.2 Rates have not slowed the pace of data center investment.2

Physical infrastructure vendors are being pulled into these commitments. Vertiv partnered with Nvidia to develop next-generation 800-volt DC power platforms designed for AI data centers.3 The partnership ties a power-equipment maker directly to Nvidia's data center roadmap.3

For investors, the pattern points to a multi-year capex supercycle rather than a single-quarter spending spike. Alphabet's guidance increase, combined with sector-wide billions commitments, suggests hyperscalers are locking in infrastructure spending on a timeline measured in years, not quarters.12

That has direct implications for suppliers. Companies in the Nvidia and Vertiv supply chain, including semiconductor makers, power management firms, and data center REITs, are positioned for capex-driven revenue as hyperscaler orders flow through 2026.3

The 800-volt DC architecture itself signals a structural shift in data center design. Higher-voltage direct current systems reduce power conversion losses at the scale AI workloads now require, a technical constraint that is reshaping how power vendors build product roadmaps around hyperscaler demand.3

Together, the three developments triangulate a single trend: neither capital costs nor macro uncertainty are slowing AI infrastructure investment. Instead, hyperscalers and their vendors are committing to buildouts spanning multiple years, with upward guidance revisions likely to continue through the rest of 2026.123

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com